Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06457503 · ClinicalTrials.gov registry record · Phase 4
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
A Phase 4 study of Nasopharyngeal Cancer Recurrent, sponsored by Coherus Oncology.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 13
- Study locations
NCT06457503 is a Phase 4 study of Nasopharyngeal Cancer Recurrent that is actively recruiting participants, run by Coherus Oncology. The registered enrollment target is 100 participants. The trial reports 13 study locations across 10 states.
The verdict
NCT06457503, a Phase 4 study of Nasopharyngeal Cancer Recurrent, is actively recruiting participants, sponsored by Coherus Oncology.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Toripalimab
Study Locations (13)
California
- University of California, Irvine - Irvine
- University of California, San Francisco - San Francisco
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Cancer Center - Detroit
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Cleveland Clinic - Cleveland
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Georgia
- Emory Winship Cancer Institute - Atlanta
Massachusetts
- Boston Medical Center - Boston
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06457503
The ClinicalTrials.gov registry entry for NCT06457503 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nasopharyngeal Cancer Recurrent appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT06457503 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT06457503 about?
NCT06457503 is a clinical study titled "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer". This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
What is the current status of trial NCT06457503?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-11-01. Estimated completion is 2027-12.
What conditions does trial NCT06457503 study?
This clinical trial studies the following conditions: Nasopharyngeal Cancer Recurrent.
What interventions are being tested in trial NCT06457503?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Toripalimab (DRUG).
Who is sponsoring clinical trial NCT06457503?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06457503 being conducted?
This trial has 13 study locations across Arkansas, California, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.